

Disclaimer

- The information contained in this confidential document ("Presentation") has been prepared by Swissray Global Healthcare Holding Limited (the "Company"). It has not been fully verified and is subject to material updating, revision and further amendment.

- While the information contained herein has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation.

- Neither the issue of this Presentation nor any part of its contents is to be taken as any form of commitment on the part of the Company to proceed with any transaction and the right is reserved to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent.

- This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this Presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.


- This Presentation includes certain statements that may be deemed "forward-looking statements". All statements in this discussion, other than statements of historical facts, that address future activities and events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those projected in forward-looking statements.



Swissray Global Healthcare Holding Ltd. (4198) Investor Conference

Gilbert Wai, CEO
December 29, 2017

Company Organizational Structure



Hochdorf, Switzerland



New Jersey, USA




Wisconsin, USA



Taipei, Taiwan

Current Product Line



New Product

■ New product: *ddRAura* Series

- C-arm type
 - *ddRAura* U
Fully automated C-arm digital radiography that supports single focus stitching function with smallest foot print.
 - *ddRAura* S
Manual C-arm digital radiography that is easy to use and with smallest foot print.
- Upgrade solution
 - *ddRAura* Drive Kit
Digital imaging upgrade solution that including a digital flat panel detector and a pad type control unit to upgrade the X-ray machine from analog or CR system to DR system.
 - *ddRAura* OptiX
A DR ready solution. A X-ray machine with high frequency generator without digital flat panel detector. It's ready to be upgraded later by installing the Drive Kit. It separates the DR budget into two small budgets for hospitals who have limited budgets to purchase capital equipment.

Business Update

■ X-ray

- Equipment sales in both US & EMEA market had a strong growth over the last fiscal year. Furthermore, Swissray's new product, *ddRAura*, has already received FDA approval and CE mark, and is being launched with a special promotion targeting toward existing users.
- Service revenue dropped- primarily resulted in expiration of the service contract with US government provider; secondly, hospital restructuring- merges of imaging centers and hospitals.

■ Bone Densitometry (Norland)

- Norland new product, ELITE, has successfully entered into the sport market. Sales record shows that 8 systems were sold and installed in 2017. Among which, two of those ELITE users are this year's top two teams in the NCAA football ranking. While ELITE demonstrated positive performance in the 1st year, XR 600 & XR 800 continue to expand its market share by signing on new distribution agreement with other countries, and also achieved solid results in the Middle East and China markets.

Business Update_ continued

■ Novadaq

- Sales steadily grows; continue to file for product registration & develop distribution network throughout the APAC regions.

■ MRI

- During mid-December, the 1st US MRI system is being installed at Ackerman Cancer Center in Jacksonville, FL, and its revenue contribution will be expected in early next year.
- Continue to promote in the US market; widen the channel to simultaneously go into distribution and direct sales.
- Plan to obtain CE mark for the EMEA market in early 2018. Started to promote *SRPulse 710* and expect a positive market response.
- Intense market competition: key competitors adjust the sales price, thus profit margins are challenged.

Business Challenges

■ Imaging Diagnosis Industry

- Competitors are all big multinational brand
- Majority of the profit is generated from service support
- Matured product, such as X-ray system, are consider low-profit product

Changes in Operating Strategy

- Adjust business model:
 - from a full scale business model
(research & development, manufacture, sales, and services)
 - ↓
 - to focus on brand channeling
(branding, channeling, & after-sales support)

- Restructure organization
 - keep minimum foot print in R&D; manufacturing inside Swiss factory
 - transform global service support team


- Budget Saving
 - control on people cost
 - minimize IT service

- Product portfolio: develop X-ray & MRI, expand product offerings through partnership.

- Focus resources on Swissray's competitive business segment.

Plan in 2018

- Top priorities: continue to reduce operating losses and improve cash inflows.
- Control expenses; further bring down overall operating expenditure.
- Uphold the value of Swissray brand in the imaging diagnosis industry by targeting on profitable segment.
- Redirect Company's resources to the future new business segment.



Swissray

New Business Development

Peter Lee, COO



Ophthalmic Optics



What is Orthokeratology (i.e. ortho-k)?

- Orthokeratology is a non-surgical, non-permanent vision correction method. An eye doctor based on certain factors to customized patient's ortho-k lens (a.k.a. plastic film), such as patient's eye refraction, corneal shape & size, and etc. Patients generally wear the lenses before bedtime and remove them in the morning, an average of 6-10 hours a day for wearing time. This is a medical treatment that does not require glasses to correct myopia.
- The origin of the word "Orthokeratology" comes from "ortho" (from Greek *orthos* 'straight, right') + "kerato" (from Greek *keras*, *kerat* 'relating to cornea') + "logy" (from Greek 'logic'). In Taiwan, we call it orthokeratology, and the lens is refer to plastic film.

What is the difference between orthokeratology lenses and contact lenses?

- General Contact Lenses

The middle portion of the interior arc is steeper and the periphery becomes flatter, which is in line with the curvature of normal cornea.

- Orthokeratology Lenses

By applying the design of reverse geometry, the central of the lens is situated flatter than the cornea in order to press on the cornea; connect externally with a steep reverse arc to set the lens and hold the corneal surface that is flattened and move to the periphery; followed by a parallel corneal radius fixed arc to maintain the stability of the lens. By using this unique design, the lens will apply pressure to the surface of the cornea, and force the epithelial cells to re-arrange during sleep. This make the top of the cornea to be flat and increase the incline at the peripheral area further reduce near sight and astigmatism.




Is Ortho-K right for you?

The following questions will validate your take that Ortho-K is a safe choice to correct ones vision:

1. You are interested in Lasik, but uncertain of its safety?
2. You can't wear contact lenses because of corneal allergic and/or sensitive?
3. You like to climb, swim, & run, but contact lenses are inconvenient?
4. Your child's eyesight increase each year and requires thicker glasses?
5. Your child needs to wear contact lenses, but always hate to wear them and/or does not clean the contact lenses thoroughly?
6. You wish that you could be like most people who doesn't have to put on glasses in the morning and go out?



Why?



Market Overview of Orthokeratology Lens in Greater China

- It is estimated that the population over the age of 5 with myopia will increase to approximately 51% in 2020 , which comes up to about 700 million of population.
- Over 75 million of elementary & middle school students are myopia.
- Laser surgery and orthokeratology lenses are the two main methods to relieve and treat myopia. As teenagers are still in their developmental stage and laser surgery is not an option, orthokeratology lenses becomes the ideal choice for this group of people to correct their vision.
- The market offers a selection of 7 brands (5 imported & 2 domestic)
- The average market price is about 6000 RMB

Market Overview of Orthokeratology Lens in Greater China (2/2)

Myopia rate of students in elementary, middle, high schools in Shanghai:


In year 2016= 37.34%, 69.00% & 85.12%

In year 1990= 16.50%, 39.80% & 68.40%


Growth rate of 20.54%, 29.20% & 16.72%



图 7、上海新世纪以来中小學生視力不良率 (%)



数据来源: wind、兴业证券研究所



Industry Gross Output

图 14、角膜塑形镜行业消费量及增长情况 (万副)




图 15、角膜塑形镜行业产值及增长情况 (亿元)



数据来源: 中国医疗器械行业协会眼科及视光学分会, 兴业证券研究所

数据来源: 中国医疗器械行业协会眼科及视光学分会, 兴业证券研究所



In 2015, the sales volume of orthokeratology lenses in China reached 643,000 pairs, an increase of 43.55% over the same period of last year.

Industry gross output reached 2.477 billion RMB, an increase of 48.68%.

Market size of simply Chinese elementary & middle school students could reach to

21 Billion in RMB


Orthokeratology Lens: Product Development Plan



Main goal: target China Market

Future focus will be the Southeast Asia market

Already acquired the 1st set of production equipment and situated the manufacture in Wisconsin, USA. Applied ISO13485 on April 22, 2017, and obtain the certification in July 2017.



Talent training in relate to manufacturing has completed.

Plan to set-up a manufacture in Taiwan, conduct clinical trials, and apply for CFDA. Estimated timeline is approximately 1-3 years.



Thank you for your time.